Tilmacoxib

Tilmacoxib
Pharmacokinetic data
Bioavailability	solution (64–88%) compared with capsule (22–40%).
Identifiers
	IUPAC name 4-(4-cyclohexyl-2-methyl-1,3-oxazol-5-yl)-2-fluorobenzenesulfonamide;
CAS Number	180200-68-4 ;
PubChem CID	159271 ;
ChemSpider	140082 ;
UNII	G6VI5P84SX ;
ChEBI	CHEBI:73041 ;
ChEMBL	ChEMBL34913 ;
CompTox Dashboard (EPA)	DTXSID0057671 ;
Chemical and physical data
Formula	C16H19FN2O3S
Molar mass	338.40 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES O=S(=O)(N)c3ccc(c1oc(nc1C2CCCCC2)C)cc3F;
	InChI InChI=1S/C16H19FN2O3S/c1-10-19-15(11-5-3-2-4-6-11)16(22-10)12-7-8-14(13(17)9-12)23(18,20)21/h7-9,11H,2-6H2,1H3,(H2,18,20,21); Key:MIMJSJSRRDZIPW-UHFFFAOYSA-N;

Last updated January 02, 2026

Tilmacoxib or JTE-522 is a COX-2 inhibitor and is an effective chemopreventive agent against rat experimental liver fibrosis.^[1]

References

↑ Yamamoto H, Kondo M, Nakamori S, Nagano H, Wakasa K, Sugita Y, et al. (August 2003). "JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis1". Gastroenterology. 125 (2): 556–71. doi: 10.1016/s0016-5085(03)00904-1 . PMID 12891558.

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Yamamoto H, Kondo M, Nakamori S, Nagano H, Wakasa K, Sugita Y, et al. (August 2003). "JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis1". Gastroenterology. 125 (2): 556–71. doi: 10.1016/s0016-5085(03)00904-1 . PMID 12891558.

[1]

Tilmacoxib

See also

References